AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01333709 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical proctectomy with total mesorectal excision
Description: The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
Study NCT03294798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum Albumin/interferon alpha2b fusion protein
Description: In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
Study NCT03294798 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: In comparator group, each subject will recieve 180mcg once per week.
Study NCT04436042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyHand Device
Description: These subjects may be asked to attend 1-40 sessions (approximately 90 mins) to trial a variety of device controls and/or components.
Study NCT02974673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ejaculatory test
Description: Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
Study NCT04235920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment (MoCA)
Description: This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
Study NCT04434872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Fecal microbiota transplantation through colonoscopy
Study NCT04434872 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Fecal microbiota transplantation through colonoscopy
Study NCT04434872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopy
Description: Fecal microbiota transplantation through gastroscopy
Study NCT04434872 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gastroscopy
Description: Fecal microbiota transplantation through gastroscopy
Study NCT04434872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota
Study NCT04434872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota
Study NCT04434872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enema
Description: Fecal microbiota transplantation through enema
Study NCT04434872 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Enema
Description: Fecal microbiota transplantation through enema
Study NCT03556332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
Study NCT03556332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
Study NCT03556332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
Study NCT03556332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle.
Study NCT03556332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic cell transplantation
Description: High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine >2mg/dL, they will receive 140 mg/m2.
Study NCT00787176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A Intravenous bolus of 1000 ml lactated ringers solution
Description: An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
Study NCT00787176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate
Description: An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
Study NCT00787176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C 125 mL/hr of lactated ringers
Description: The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
Study NCT03066492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Northwestern Follow Up Care Coordination
Description: Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
Study NCT03066492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Federally Qualified Health Center
Description: Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
Study NCT01828463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: doses 1, 2, 4 \& 8 mg plus no treatment arm
Study NCT05373420 — intervention group
Intervention type: OTHER
Intervention: Migration background
Description: Migration background is based on the first nationality and the parents' country of origin. This variable distinguishes between native-born individuals, second-generation migrants, first-generation European migrants, and first-generation non-European migrants. This information is provided by STATBEL.
Study NCT05373420 — intervention group
Intervention type: OTHER
Intervention: Household type
Description: Household type provides a partial picture of the social environment and is distinguished between one person, couples, couples with children, single parents, other, collectivity (prison, nursing homes, religious community, etc.). This information is provided by STATBEL.
Study NCT05373420 — intervention group
Intervention type: OTHER
Intervention: Health literacy
Description: Having a health care degree is used as a proxy for health literacy and is provided by CoBRHA. The scientific and medical background can lead to more preventive and responsible behaviors towards infectious diseases. Moreover, being a health professional can lead to the need to protect patients and themselves against infections, without necessarily having very advanced knowledge of infectious diseases and vaccines.
Study NCT02007876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility and Activity Training
Description: Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2.
Study NCT00893087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering mode of the ventilator
Description: 10 min of each triggering mode
Study NCT02443311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Description: Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
Study NCT00893087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering method of the ventilator
Description: Flow triggering
Study NCT00893087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering method of the ventilator
Description: Pressure triggering
Study NCT00893087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering method of the ventilator
Description: NAVA triggering
Study NCT00982488 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Dasatinib was supplied as 20- and 50-mg tablets.
Study NCT00982488 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Imatinib was supplied as 100- and 400-mg tablets.
Study NCT00320099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human insulin
Description: intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
Study NCT00320099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: 50 mg as iv bolus every 6 hours for 7 days
Study NCT00320099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 50 mg as iv bolus every 6 hours for 7 days
Study NCT00320099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludrocortisone
Description: 50 µg once a day via a nasogastric tube for seven days
Study NCT00320099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: hydrocortisone 50mg q6 for 7 days
Study NCT01148745 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ferumoxytol
Description: 510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
Study NCT00950547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARDIOPAT
Description: Cell Saver System at bedside for ICU stay
Study NCT02443311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone 17-valerate 0.1% cream
Description: Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
Study NCT00950547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chest Drains
Description: Chest drains as usual with no possibility to reinfuse lost blood
Study NCT00195182 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self affirmation and positive affect induction vs. control
Description: During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
Study NCT00505843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MK0657
Description: 7mg MK0657 capsules
Study NCT00505843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Placebo (unspecified)
Description: 7mg MK0657 Pbo capsules
Study NCT00505843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: levodopa
Description: levodopa >/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
Study NCT00505843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: carbidopa
Description: carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
Study NCT02949492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 (interleukin 2)
Description: Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
Study NCT01477060 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib
Description: 1250 mg/ die, os
Study NCT01477060 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 1500 mg/die, os
Study NCT05690555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Physical Therapy (PFPT)
Description: Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~* Subjective assessment of bowel and bladder function~* Visual and external palpation and assessment of external pelvic floor region~* Intravaginal pelvic floor assessment~* Pelvic floor muscle dynamics and coordination assessment~* Instruction of pelvic floor coordination and lengthening~* Discussion of dilator program and progression~* Home program with instructions~  6 weeks:~* External scar assessment and treatment if tissue healing allows~* Instruction to patient of scar mobilizations~* Intravaginal pelvic floor assessment and treatment if indicated~* Review of pelvic floor lengthening and coordination~* Review and progression of dilator program if appropriate~* Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms
Study NCT05690555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Pelvic Floor Physical Therapy (PFPT)
Description: Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function.
Study NCT05690555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative PFPT and Postoperative PFPT
Description: Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions
Study NCT05690555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-over Treatment
Description: Any patients in the No PFPT arm who are determined to have pelvic floor dysfunction or symptoms that may benefit from PFPT referral, will be referred after the 12-week mark. Any patient in one of the PFPT arms who is determined to still need PFPT for persistent pelvic floor dysfunction or symptoms will be referred for continued care.
Study NCT03395912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention
Description: After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
Study NCT04469114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge
Study NCT04469114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
Study NCT03120546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rigid video stylet intubation
Description: intubation using rigid video stylet
Study NCT03120546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope intubation
Description: intubation using video laryngoscope
Study NCT02809690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAT
Description: Undergo 18F-FMAU PET/CT
Study NCT02809690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMAU
Description: Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
Study NCT02809690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02809690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo mpMRI
Study NCT02809690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FMAU PET/CT
Study NCT02809690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo TRUS-guided biopsy
Study NCT01199289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: SC injection.
Study NCT01199289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection.
Study NCT04355325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified monolithic zirconia crowns
Description: outcomes and complications of implant restoration
Study NCT04355325 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: modified monolithic zirconia crowns
Description: outcomes and complications of implant restoration
Study NCT04355325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal Ceramic crowns
Description: outcomes and complications of implant restoration
Study NCT04355325 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Metal Ceramic crowns
Description: outcomes and complications of implant restoration
Study NCT01852942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
Study NCT01852942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet by mouth daily
Study NCT01154218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC
Study NCT00874354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracoronary Transplantation of Bone Marrow Stem Cells
Description: Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
Study NCT03631901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral melatonin
Description: Both melatonin and diazepam were given only during the febrile illness.
Study NCT03631901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral diazepam
Description: Both melatonin and diazepam were given only during the febrile illness.
Study NCT03613935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 1
Description: Comparison with products 2, 3, and 4